ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 188,49
-0,63%
Dow Jones
39 869,38
-0,10%
DAX
18 738,81
-0,72%
Brent Oil
83,14
-0,08%
Bitcoin
65 270,77
0,05%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Assembly Biosciences Inc (ASMB)

  7. Assembly Biosciences Inc (ASMB) Actualités

ASMB

Assembly Biosciences (ASMB)

Assembly Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ASMB
DateHeureSourceTitreSymboleSociété
08/05/202422h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ASMBAssembly Biosciences Inc
08/05/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ASMBAssembly Biosciences Inc
08/05/202422h05GlobeNewswire Inc.Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent HighlightsNASDAQ:ASMBAssembly Biosciences Inc
28/03/202421h05GlobeNewswire Inc.Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent HighlightsNASDAQ:ASMBAssembly Biosciences Inc
08/02/202414h00GlobeNewswire Inc.Assembly Biosciences Announces Effective Date of Reverse Stock SplitNASDAQ:ASMBAssembly Biosciences Inc
19/01/202417h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ASMBAssembly Biosciences Inc
04/01/202414h00GlobeNewswire Inc.Assembly Biosciences Provides Anticipated Development Milestones for 2024NASDAQ:ASMBAssembly Biosciences Inc
21/12/202322h06Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ASMBAssembly Biosciences Inc
21/12/202322h01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ASMBAssembly Biosciences Inc
11/12/202322h10Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ASMBAssembly Biosciences Inc
11/12/202322h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ASMBAssembly Biosciences Inc
22/11/202322h12Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ASMBAssembly Biosciences Inc
10/11/202322h05GlobeNewswire Inc.Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ASMBAssembly Biosciences Inc
10/11/202314h00GlobeNewswire Inc.Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®NASDAQ:ASMBAssembly Biosciences Inc
08/11/202322h05GlobeNewswire Inc.Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent UpdatesNASDAQ:ASMBAssembly Biosciences Inc
08/11/202314h00GlobeNewswire Inc.Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical OfficerNASDAQ:ASMBAssembly Biosciences Inc
31/10/202321h19Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:ASMBAssembly Biosciences Inc
17/10/202314h44Dow Jones NewsAssembly Biosciences Shares Soar Premarket on Gilead PactNASDAQ:ASMBAssembly Biosciences Inc
17/10/202313h51Dow Jones NewsGilead Taking Stake in Assembly Bio Under Antiviral CollaborationNASDAQ:ASMBAssembly Biosciences Inc
17/10/202313h00Business WireGilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral DiseasesNASDAQ:ASMBAssembly Biosciences Inc
11/10/202314h00GlobeNewswire Inc.Assembly Biosciences to Present New Data at AASLD The Liver Meeting®NASDAQ:ASMBAssembly Biosciences Inc
04/10/202301h20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASMBAssembly Biosciences Inc
02/10/202314h00GlobeNewswire Inc.Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry InhibitorNASDAQ:ASMBAssembly Biosciences Inc
19/09/202322h05GlobeNewswire Inc.Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV MeetingNASDAQ:ASMBAssembly Biosciences Inc
09/08/202322h28Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ASMBAssembly Biosciences Inc
09/08/202322h05GlobeNewswire Inc.Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent UpdatesNASDAQ:ASMBAssembly Biosciences Inc
17/07/202314h00GlobeNewswire Inc.Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus WorkshopNASDAQ:ASMBAssembly Biosciences Inc
24/06/202301h05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ASMBAssembly Biosciences Inc
21/06/202314h00GlobeNewswire Inc.Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023NASDAQ:ASMBAssembly Biosciences Inc
07/06/202314h00GlobeNewswire Inc.Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023NASDAQ:ASMBAssembly Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:ASMB

Dernières Valeurs Consultées

EU
CAP
Capgemini
EU
LR
Legrand
EU
DG
Vinci
EU
VK
Vallourec
EU
BNP
BNP Paribas
EU
PX1
CAC 40
COIN
ETHUSD
Ethereum
EU
ACA
Credit Agricole
EU
CS
Axa
EU
RNO
Renault
EU
PX4
SBF 120
FTSE
UKX
FTSE 100
EU
ORA
Orange
EU
AF
Air FranceKLM
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés